Globus Medical Inc. (NYSE: NYSE:GMED), a prominent medical device company, has reported robust financial results for the second quarter of 2024. The company experienced a significant increase in sales, reaching $630 million, which marks a 116% growth compared to the previous year. Non-GAAP earnings per share (EPS) also saw a healthy rise, amounting to $0.75, a 20% increase year-over-year.
These results were bolstered by the successful integration of NuVasive (NASDAQ:NUVA), a recent acquisition that has contributed substantially to the company's performance. Despite not offering specific future guidance, Globus Medical remains optimistic about its growth trajectory and the continued adoption of its technology in the market.
Key Takeaways
- Globus Medical reported a 115.9% increase in Q2 revenue, totaling $629.7 million.
- GAAP net income reached $31.8 million, with non-GAAP net income at $102.7 million, up 61.5%.
- The company launched four new products and expects a record number of launches in the coming months.
- Sales in U.S. spine, international spinal implants, and the combined trauma and NSO business saw significant growth.
- Full-year net sales are projected to be between $2.47 billion and $2.49 billion, with non-GAAP EPS expected to range from $2.80 to $2.90.
- Globus Medical aims to achieve $170 million in cost synergies and a mid-70s gross profit profile in the long term.
Company Outlook
- Anticipates a slight step-down in EBITDA margin in Q3 due to lower revenue projections.
- Remains committed to a long-term growth strategy, focusing on robotics technology and expanding market penetration.
- Expects to return to a mid-70s gross profit profile and achieve $170 million in cost synergies.
Bearish Highlights
- Acknowledged the presence of competition in the market.
- Noted potential dissynergy, with a clearer picture expected in 12 to 18 months.
Bullish Highlights
- Musculoskeletal revenue grew by 130.8%, largely driven by the NuVasive merger.
- Enabling technology sales, including robotics, increased by 5.8%.
- Expressed confidence in the commercial strategy and technology adoption.
Misses
- The company did not provide specific future guidance but plans to reevaluate after the third quarter.
Q&A Highlights
- Discussed the importance of new product launches to counter pricing pressures.
- Emphasized the growth potential through cross-selling opportunities and team integration.
- Highlighted the rental program for enabling technology, driven by customer preference, without significant risk to revenue targets.
- Stated the intention to settle convertible notes due in March in cash.
Globus Medical's second-quarter performance reflects a strong financial position and a strategic focus on growth through product innovation and market expansion. The company has made significant strides in its U.S. and international sales, particularly in the spine and trauma sectors, and is leveraging its enabling technology to drive further adoption. While aware of the competitive landscape and potential operational challenges, Globus Medical is committed to maintaining financial discipline and delivering on its long-term objectives. With additional product launches on the horizon and a clear strategy for market penetration, the company is poised for continued success.
InvestingPro Insights
Globus Medical Inc. (NYSE: GMED) has demonstrated a remarkable surge in revenue, with the last twelve months as of Q2 2024 showing a 103.89% increase, signaling strong market performance and successful strategic initiatives. The company's robust growth is also reflected in its share price, which is trading near its 52-week high, at 96.89% of this peak value. This aligns with the company's positive trajectory and investor confidence in its expansion and product integration efforts.
InvestingPro Tips suggest that management's aggressive share buyback strategy is a vote of confidence in the company's value, while analysts forecast profitability for GMED in the upcoming year. This is consistent with the company's optimistic outlook and its ongoing efforts to innovate and capture market share, especially following its integration of NuVasive. Furthermore, GMED's stock has shown low price volatility, which may appeal to investors seeking stability in their portfolio.
For investors looking for more in-depth analysis, there are 15 additional InvestingPro Tips available, providing a comprehensive view of GMED's financial health and market position. With a current market capitalization of $9.71 billion and a high P/E ratio of 231.76, it's clear that the market has high expectations for the company's future earnings. However, the adjusted P/E ratio for the last twelve months sits at a more moderate 54.3, suggesting a more nuanced picture of the company's valuation.
Investors can access these insights and more by visiting the dedicated page for Globus Medical on InvestingPro, which offers a full suite of tools and data for a deeper dive into the company's financials and market performance.
Full transcript - Globus Medical (GMED) Q2 2024:
Operator: Welcome to Globus Medical's Second Quarter 2024 Earnings Call. At this time, all lines will be on mute and a Q&A session will be held after the prepared remarks. I'll now turn the call over to Brian Kearns, Senior Vice President of Business Development and Investor Relations. Mr. Kearns, please go ahead.
Brian Kearns: Thank you, Stephen, and thank you, everyone, for being with us today. Joining today's call from Globus Medical will be Dan Scavilla, President and Chief Executive Officer; and Keith Pfeil, Chief Operating Officer and Chief Financial Officer. This review is being made available via webcast accessible through the Investor Relations section of the Globus Medical website at www.globusmedical.com. Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements. Our Form 10-K for the 2023 fiscal year and our subsequent filings with the Securities and Exchange Commission identify certain factors that could cause our actual results to differ materially from those projected in any forward-looking statements made today. Our SEC filings, including the 10-K, are available on our website. We do not undertake to update any forward-looking statements as a result of new information or future events or developments. Our discussion today will also include certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP. We believe these non-GAAP financial measures provide additional information pertinent to our business performance. These non-GAAP financial measures should not be considered replacements for and should be read together with the most directly comparable GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are available in the schedules accompanying the press release and on the Investor Relations section of the Globus Medical website. With that, I'll now turn the call over to Dan Scavilla, our President and CEO.
Daniel Scavilla: Thanks, Brian, and good afternoon, everyone. Globus delivered another robust post-merger quarter in Q2 with sales of $630 million, growing 116% or $338 million. Non-GAAP EPS was $0.75, increasing 20% versus prior year, even with the 35% increase in outstanding shares driven by the merger. Free cash flow was $26 million for the quarter and adjusted EBITDA cross 30%, as we build our way back to the mid-30s range. Q2 is the second quarter where we integrated the Globus and NuVasive field organizations into one formidable team, rolling out new reporting structures globally, combining product portfolios to create best-in-class offerings to our surgeons, reorganizing support organizations, implementing common systems, and beginning to unlock synergies to drive future growth. Through all of this change, Globus launched four new products in Q2, reaching nine product launches year-to-date, and has set the stage for a record number of launches in the coming months. These results are testament to our incredible team working tirelessly around the clock to drive integration, overcome challenges, and create scalable solutions so that we can reach steady state quickly and shape the markets in which we compete. Focusing on the performance of our business, U.S. spine grew 100% in Q2, with notable gains across our product portfolio in expandables, biologics, MIS screws, and cervical offerings, including Simplify Cervical Disc. This growth is driven by the strength of our combined product offering, competitive rep recruiting from prior quarters, and increased implant usage through robotic pull-through. Competitive rep recruiting remains solid through Q2, and the pipeline is growing. As mentioned in the last earnings call, now, more than any point in our history, the most successful and tenured competitive professional reps are seeking to join our team. Competitive reps with over 10 years of tenure, once a rarity to recruit, are seeing the power and future we can offer them as a destination of choice for innovation and growth. 2024 has the potential to be a record recruiting year. On the product development front, we continue to execute, launching four new products from our prolific R&D pipeline. The combined product development team has hit its stride with meaningful collaboration in developing and launching new products, and we expect these to continue at this accelerated pace due to improved development processes. I want to share these meaningful launches with you. REVEL-S is an expandable, standalone ACDF spacer system delivered at a minimized height to reduce impaction and tissue retraction, while providing controlled, continuous expansion to help restore disc height and sagittal balance. In situ bone delivery allows for additional bone graft to be introduced after expansion, to help promote fusion. HILINE is a versatile posterior band fixation system for the cervical and thoracolumbar spine, featuring robust implants and advanced instruments. The system is engineered to help achieve strong reduction during deformity correction, provide reliable stabilization and compromised anatomy, and facilitate ligament augmentation. The XLIF prone system is yet another testament to our commitment to advancing XLIF procedural solutions, with dedicated instruments and positioner combined with EGPS and E3D. The system is designed to improve the safety, reliability, and reproducibility of the XLIF procedure, emphasizing secure patient positioning, MaXcess retractor stability, and surgeon ergonomics. AUTOBAHN PRO instruments and digital targeting system are next generation instruments for trochanteric nailing that allow for streamlined surgical workflow. The procedural targeting solution features a minimally invasive aiming handle, targeted anti-rotation wires, self-retaining sleeves, and tactile compression, while the universal nailing instruments improve efficiency for the AUTOBAHN PRO Troch Nail and the AUTOBAHN EVO Femoral Nail platforms. In addition to driving growth from the nine products we've launched so far this year, I look forward to sharing future impact with launches as we go through the rest of 2024. Enabling technology sales were $37 million, up 6% versus prior year. Q2 was the highest number of robot unit placements since launch, growing 59% over prior Q2, including the acceleration of our rental program where, unlike a unit sale, we recognized revenue over the rental contract life. Robotic procedures continue to accelerate, growing 26% versus prior year, and exceeding 77,000 robotic procedures performed since launch. We are adding NuVasive products such as RELINE and Modulus to our enabling tech platform to expand customer options and plan on offering this later this year. Exiting Q2, our robot pipeline is healthy, and we are poised to have a great second-half robotic performance. We also continue to penetrate the market with Excelsius 3D imaging systems, and market interest remains high for E3D as we enter Q3. Our international spinal implant business delivered record sales in Q2, growing 200% on a constant currency basis, compared to prior year. Globus increased investment in our international business for people, products, and sets, and we have achieved consistent above-market growth throughout these regions as a result. We have yet to fully harness the power of the combined Globus and NuVasive product offerings internationally and feel this will be a significant tailwind moving forward. The combined trauma and NSO business delivered 321% growth for Q2, driven by the continued powerful performance and market penetration of our base trauma business, combined with the fast uptake of the NuVasive specialty orthopedic growth now. The combination of these two businesses is one of the strengths of our merger, offering a broad range of products and market-changing innovation. Late in Q2, we received FDA 510(k) clearance for two significant components of our arthroplasty business. Joining the already best-in-class Excelsius ecosystem is the Excelsius Flex (NASDAQ:FLEX) robotic navigation platform, paired with the Excelsius Flex TKA, a total knee arthroplasty application, designed to enable consistent, accurate cuts while maintaining surgeon flexibility and tactile feel. It accommodates varying surgeon preferences by offering imageless and CT-based workflows, and ergonomic, unrestricted, jiggles resections. Excelsius Flex TKA is engineered to restore control of the sole and the procedure to the surgeon while active tracking is engaged. The system features advanced registration and planning algorithms to enable a streamlined and efficient procedure, along with a simplified user interface. The Actify 3D total knee system is a contemporary total knee solution that pairs cementless reconstruction with operative efficiency and anatomic fit. Compatible with manual or robotic-assisted workflows, Actify 3D is engineered to combine implant endurance and a porous lattice interface for cementless fixation, addressing surgeon preference and varying patient anatomies. Launch programs have begun for these products as we continue to expand our direct sales force to penetrate the market later this year. Invasive clinical services is a key element in our proceduralization strategy and cross-selling synergies, growing 5% on a pro forma basis. Globus is investing in expanding our neuromonitoring inventory worldwide to ensure that NCS neuromonitoring is used in more of our procedures. Looking ahead, we've begun investing in next generation systems that will expand surgical applications and add more signal analytics, automation, and seamless integration with our enabling technologies. Moving into integration status, we continue to invest in our field sales teams with product cross-training, enabling tech hands-on experience and significant investment in key product sets, so they can increase their growth opportunities and offerings to their surgeons through cross-selling. We have implemented common operating systems in the U.S., allowing us to work as one company and one team. International system synergies will start later this year. In product development, we are carrying forward the rich history of rapid development as an industry thought leader as we work with our surgeon partners, to address some of our clinical needs. From pioneering the XLIF procedure that is now the gold standard of lateral surgery, leading the market in expandable spacer technology, and developing the best spinal robot with the most advanced interoperative CT imaging, we are working to create surgical proceduralization of all key spine surgeries to create the standard of care across the spine industry. Our intellectual property portfolio has been number one in the spinal industry for the last decade, and Globus is committed to further expanding this lead, especially in the enabling tech arenas, as we continue to be at the forefront of imaging, navigation, and robotics. To accomplish this, we remain committed to continuing existing projects, and we'll have an ongoing PD presence on the West Coast focused on spine and neuromonitoring solutions. I believe our long-term prospects as a leading innovator have never been stronger. We continue to enhance our surgeon engagement programs to increase our impact with surgeons, and further strengthen how we interact with them in all aspects of our business, through professional affairs, scientific affairs, marketing, and education. In the second quarter alone, we trained over 400 surgeons globally through MERC programs and case observations, and in addition, hosted approximately 250 surgeon in-house visits or VIPs where they learned about products and programs through hands-on training. As you can see from this quarter's financials, synergies have been identified, and actions have begun to be realized for benefits focusing on out-of-pocket spending and prioritizing investments to match future growth plans. In-house organizational structures have been implemented, and we're working towards reaching steady state in the second half of the year. I believe the potential for Globus has never been greater. It's up to us to harness our resources and shape the future of our markets. We have at our fingertips everything we need to realize this. I want to thank the worldwide Globus team, for your dedication and support, delivering an incredible quarter, and furthering the pathway to becoming the preeminent musculoskeletal technology company in the world. I will now turn the call over to Keith.
Keith Pfeil: Thanks, Dan, and good afternoon, everyone. Momentum at Globus continues to grow, as we've completed another impressive quarter since the closing of our transformational merger on September 1, 2023. Commercially, our teams have forged deeper bonds and continue on a path of growth. Operationally, we've remained heads down to realize efficiencies of plans put into place, while preparing for the next wave of investments to drive greater efficiencies looking ahead. Our drive for profitable growth and prudent cost control remains energized in our culture as we chart our path forward, and the second quarter results demonstrate our steadfast commitment. Digging into the second quarter, revenue was $629.7 million, growing 115.9% as reported and 117.3% on a constant currency basis. Day adjusted growth was 113%, with one more selling day in the U.S. and international, as compared to Q2 of 2023. Our Q2 GAAP net income was $31.8 million, resulting in $0.23 of fully diluted earnings per share. Q2, '24 non-GAAP net income was $102.7 million, delivering $0.75 of fully diluted non-GAAP earnings per share. The second quarter non-GAAP net income grew 61.5% over the prior year quarter, while earnings per share grew 20%. However, as Dan commented on earlier, non-GAAP EPS was impacted by a 35% increase in diluted shares as a result of the merger. Q2 adjusted EBITDA was 30.2%, and free cash flow was $26.5 million. Musculoskeletal revenue in the second quarter was $592.9 million, growing 130.8% compared to the prior year quarter, driven primarily from the contributions of the NuVasive merger. On a pro forma basis, assuming NuVasive was in our prior period results, musculoskeletal revenue grew 3.7% versus the prior year quarter. This is the third consecutive quarter of pro forma musculoskeletal revenue growth driven primarily by our U.S. and international spine businesses, as well as our combined trauma portfolios. Enabling Technologies revenue grew 5.8% in the second quarter compared to the prior year quarter. Revenue growth was strongest in the U.S. market, however it was partially impacted by a higher mix of rentals during the quarter. Overall, our second quarter stands as the highest quarter ever for combined capital units and highest EGPS robotic units moved during a quarter, whether an outright purchase, rental, lease, or volume-based arrangement. As we look ahead, we remain well positioned to further penetrate the market with our suite of Excelsius technologies. Our second quarter U.S. revenue was $499.5 million, growing 103.5% as reported, compared to the prior year quarter. On a pro forma basis, U.S. revenue grew 3.1%, compared to the prior year quarter, driven by contributions from spine, trauma, and enabling technologies. I call attention to the fact that we've experienced U.S. sales growth on a pro forma basis in each full quarter of results since the merger with NuVasive. International revenue during the second quarter was $130.2 million, growing 182.3% on an as reported basis, compared to the prior year quarter. On a pro forma basis, international revenue grew 4.4% as reported, led by strong implant uptake partially offset by lower capital sales, primarily as a result of lower pulse unit sales. Our growth of implant sales were strongest in the EMEA and LATAM regions. GAAP gross profit was 58.7% in the second quarter of 2024, compared to 73.8% in the prior year quarter. Consistent with commentary from previous quarters, the decline in gross profit is associated with the NuVasive merger, namely step-up amortization. As a reminder, step-up amortization is expected to end during our fiscal fourth quarter. Excluding the impacts of step-up amortization, adjusted gross profit was 67.2%. The decline in adjusted gross profit is driven largely by the inclusion of NuVasive in our consolidated results, as well as some higher non-recurring inventory reserve expenses. Consistent with my comments last quarter, we still expect the full-year adjusted gross profit rate to be in the mid-to-upper 60s for the full year of 2024. Our longer-term goal is to return to a mid-70s gross profit profile, which will be achieved through insourcing actions with our year two and year three cost synergy plans. Research and development expenses in the second quarter were $37.7 million, or 6% of sales, compared to $21.3 million, or 7.3% of sales, in the prior year quarter. The increase in spending is primarily the result of the inclusion of NuVasive in our consolidated results, partially offset by the impact of cost synergy actions taken. Looking ahead, we now expect full-year R&D expense to be in the range of 6.5% to 7% for the full year of 2024. SG&A expenses in the second quarter of 2024 were $238.1 million, or 37.8% of sales, compared to $120.1 million, or 41.2% of sales, in the second quarter of the prior year. The increase in total SG&A dollars is directly the result of the NuVasive merger, partially offset by cost actions taken, as well as fixed cost leverage on spending. Looking ahead, our expectation is that full-year SG&A expenses will improve one to two percentage points over the full year 2023 SG&A expense as a percentage of sales. Net interest expense during the second quarter of 2024 was $2.3 million, compared to net interest income of $8.3 million in the prior year quarter. The resulting $10.6 million pre-tax unfavorable impact is driven by the use of cash to fund a NuVasive line of credit paydown at merger close, share purchases related to our buyback plan, and interest expense from the senior convertible note, which is assumed from NuVasive at merger close. The GAAP tax rate for the second quarter was 33.2%, compared to 22.7% in the prior year quarter, driven primarily by higher valuation allowances on foreign losses. Our non-GAAP tax rate during the second quarter was 24.4%. We expect our full year non-GAAP tax rate to be in the range of 24% to 25%. Moving over to cash and liquidity, our cash, cash equivalents, and marketable securities were $520.7 million at June 30, 2024. Since the merger closed, we spent a total of $731.1 million to fund the NuVa line of credit pay down, which was $420.8 million, as well as $310.3 million on share repurchases. We did not have any short-term borrowings against our line of credit, and our only long-term debt consists of the 0.375% senior convertible notes due in 2025. Our intent remains focused on settling these notes when they are due in March of 2025. Our Q2 net cash provided by operating activities was $54.3 million, and free cash flow was $26.5 million. Consistent with my comments during our last quarterly call, we expect a temporary impact to operating cash flow, as a result of higher accounts receivable balances driven by the systems integration and U.S. Go Live. This temporary delay impacted the first and second quarters, reflected as a higher working capital investment in accounts receivable. We have no concerns regarding the collectability and expect to see higher cash collections during our third and fourth quarters. Capital expenditures during the second quarter were $27.8 million, or 4.4% of revenue. We expect full year 2024, CapEx to be in the range of 4.5% to 5.5% of sales. Shifting attention to integration, we continue to invest in our field sales team, with high investments in new sets, product cross-training, and enabling tech hands-on experience so we can drive increased commercial growth opportunities, by providing expanded offerings to their surgeons. Earlier this year, we rolled out a common operating system in the U.S. and are continuing to refine plans, to begin rolling this out to our international businesses later this year, which will allow us to work as one team globally. Operations remains a strength of the merger. We are actively executing our plans around renegotiating supplier costs, and investing in new machinery and equipment to expand our in-house manufacturing capabilities, which will drive planned cost synergies faster. We are also working to consolidate volumes and orders with third-party vendors to accelerate delivery times and drive cost savings. The Memphis Distribution Center is now on a common operating system and becoming a larger part of the overall Globus business. All activities are progressing to plan. We are actively working now on synergies that will drive year two and year three savings. We again reaffirm our commitment to achieving the $170 million in cost synergies. We remain upbeat and confident with our results thus far and expect an enduring focus on commercial growth and operational execution as we enter the back half of the year. Based on that, we are updating our previously provided guidance. We now expect 2024 net sales to be in the range of $2.47 billion to $2.49 billion and our fully diluted non-GAAP earnings per share to be in the range of $2.80 to $2.90 per share. A revised net sales guidance implies 3.1% to 3.9% growth over 2023 pro forma revenues of $2.396 billion. The revised non-GAAP EPS guidance implies 20.7% to 25% growth over the prior year non-GAAP EPS of $2.32 despite a higher share count, due to the stock-for-stock merger. We remain appropriately conservative with our projections, though as we continue to gain more and more confidence, as we enter the second half of the year. In closing, I want to take a minute to thank our team. We've driven a lot of change internally and our team has stood up to the challenge. Bringing together these two great companies has been an opportunity for us to create the leading med-tech company in our space. We have the technology, we have the manufacturing and supply chain, we have the financial resources, and most importantly, we have the people to take us to new heights and drive positive change to achieve our mission. We will remain steadfast in our pursuit of sales growth in a financially responsible manner, adhering to historical Globus principles. Operator, we will now open the call for questions.
Operator: Thank you. [Operator Instructions] Our first question comes from the line of Matt Miksic of Barclays (LON:BARC). Your line is now open.
Matthew Miksic: Hi, thanks so much for taking the questions and congrats on a really strong quarter and great results here in the first half. So I had one kind of multi-part question, but kind of the same subject. It's really just around the sort of plans that you laid out, when you initiated the acquisition of NuVasive and sort of the pro forma numbers that you've been referencing. I think we're all familiar with over the last year, year and a half. And just trying to get a sense of at what point should we expect you to start, given that things are going, I'd say, better than expected, a simple way to put it. At what point should we expect you to start updating those numbers, maybe for the full front-to-back integration? And then also, at what point might you start to talk a little bit about if there's intermediate and long-term opportunity here? So, not to look at the success of the first half and how great everything is going now. That kind of color would be super helpful? Thanks so much.
Keith Pfeil: Sure. Matt, this is Keith. I'm going to take the first part of your question, and Dan will take the second part. So, to your comment, we've gotten off to a strong start. I think messaging-wise, when we talked about when the deal was announced in February of 23, as well as when the deal closed in September, we remained very steadfast on, to me, the merger thesis of why we were bringing the companies together, and with that, the cost synergies that we identified in terms of the number, the $170 million, as well as where we thought there would be cross-selling opportunities for us to move forward. We've gotten off to a strong start, especially in the light of some of the, really, negativity as it relates to the merger at the outset. But Dan and I have been consistent that as each quarter gets past, we get more and more confident. We're coming up, we're basically into the 11th month now of the companies being together. I think after we get through this third quarter, you'll start to see us take a look back, recast how we performed in the first 12 months of the companies being together. And help provide some insights as we move forward. But, you know, standing here today, like I said in my prepared remarks, we feel good about the $170 million, and really the attention is shifting towards years two, and years three as it relates to insourcing and getting that gross profitability back up to the mid-70s gross profit profile, which Globus has historically been known for.
Daniel Scavilla: Yes, Matt, I'll build in on that. So obviously Keith and the team are going to look at projections of where we're going to go for the rest of this year, roll that into 2025. We're also going to take that into a longer-term three and five-year plan as we develop a strategic plan. We'll share some of that, certainly, when we get into our Investor Day coming up. That's really where I think you'll see more from that. Again, as you know and what we'll always do, anything long-term like that is directional. It's not going to be a commitment for us to do, but rather what we project from what we see. So I would say stay tuned. I think we want to get through the third quarter, fine-tune where we want to be. We'll share what we think the year or next year could be. And then longer-term projections based on those assumptions.
Matthew Miksic: Great. Thanks so much.
Operator: Thank you. Our next question comes from the line of Vik Chopra of Wells Fargo (NYSE:WFC). Your line is now open.
Vikramjeet Chopra: Hi, good afternoon, and thanks for taking the questions. Also, congratulations on a great quarter. Two from me, one, you put up 30.2% EBITDA margin in Q2, well ahead of expectations. How should we think about margins for the full year? And then I had a follow-up, please?
Keith Pfeil: Sure. So thanks, Vik. As I think about the full year, I think we're going to - we don't necessarily give EBITDA guidance, but I think as we move forward, you'll see a little bit of a step-down as we move forward into Q3, and that's really predicated on what we expect in Q3 with really a sequential step-down in revenue. We're thinking that Q3 is going to look a little bit like fiscal '22 when you look at revenues from Q2 to Q3. That, coupled with additional capital sales, will create a little bit of a headwind on EBITDA. But for the full year, we're sitting here today, we did 30%, a little over 30% in Q2. I still think it'll be difficult to get to 30% for the full year, but I think we're going to work to get closer to that.
Vikramjeet Chopra: Great. Thanks for that question. And then my follow-up question, I just wanted to ask you what you're seeing on the capital side. One of the large [O2PT] competitors has talked about coming out with a spine robot at the end of the year. And another competitor recently received FDA approval for their spine robot. Just talk about the market and the competitive landscape? Thanks so much.
Daniel Scavilla: Thanks, Vik. I'll take that. So a couple things, right? Keep in mind that we have been executing our long-term enabling tech plan, and there's nothing that's occurred that would have us deviate from that. We'll take our existing technology and continue to expand its applications through proceduralization, things we've talked about openly with that. As you recall, one of the main drivers of the merger was to, in fact, increase our company total available market and create more areas for rapid penetration. So while we take any entrance seriously, and we'll look at that, there's nothing that's occurred that has shifted the capital market in which we play or altered our plans at this point from where we're going. I would tell you, I was very pleased with where we were in Q2, and with the portfolio we're working on in Q3, it's one of the strongest. And so, we'll continue to execute and stay focused.
Operator: Thank you. Our next question comes from the line of Shagun Singh of RBC (TSX:RY) CM (TSX:CM). Your line is now open.
Shagun Singh: Great. Thank you so much, and congratulations. A lot of bright spots here. I wanted to focus on robotics. I'm just wondering if you can share, provide any incremental color on, you know, why you think such strong growth? Are you seeing the benefit of the combined sales force? What does the pipeline look like? And I guess I'm just wondering, is it possible for you to double the pace of your placements given the doubling of your sales force, as we head into 2025? And then I have a follow-up.
Daniel Scavilla: Thanks, Shagun. I'll take that. I'll start backwards. I would love to double the uptake of that. And we certainly have that potential. I think what you're seeing right now is, first off, the market's willingness and continued willingness to adopt the technology. So you're no longer really fighting or pushing to get it in there. Folks are actually pulling it with you, which helps. And so that's really part of the thing that's occurring that way. It has been primarily Globus focused to this point because, as I've said, we're still working on the Reline, the Modulus, other type things that will make our technology more applicable to new users. But, again, I think that's coming within the second half of the year. And when we do that, I do think we'll see an acceleration. Probably not going to sign up for doubling, but I'll certainly push to try and do that, and we'll see where we get to.
Shagun Singh: Got it. That's helpful. And then just on the ReconRobotic, can you talk about what exactly you've differentiated in your system versus a Mako and a ROSA? And can you elaborate on your commercial strategy since it's an already well-penetrated market? That would be helpful. Thank you so much.
Daniel Scavilla: No, no problem. So I won't elaborate on the commercial strategy. I want to go execute that and not lay that bear out for everybody to react to. So let's go back and do it that way. And rather than puts and takes of the robot having it just been approved, we're developing out our approach with this. And while I do think there's differentiating technology and I'm excited to get it out there, I don't want to go head-to-head or compare that right now on this call, but I'll be glad to do that with you at some point offline as we take this further down the path.
Shagun Singh: Thank you.
Operator: Thank you. Our next question comes from the line of Steve Lichtman of Oppenheimer. Your line is now open.
Steve Lichtman: Thank you. Evening, guys. Dan, you're giving your market share now in spine. I was hoping you can give an update on where you think U.S. market growth is now, and as you look back at the first half of this year on a pro forma basis, where do you put your growth relative to where you think the market is? And if you could talk a little bit about unit growth in pricing, that would be great.
Daniel Scavilla: Yes, Steve will do. So I would tell you we don't have anything significant in pricing. We've always tracked along with low single digits with that, and for the most part I would say we still adhere to that. There's nothing that's occurred from the market or from our growth that is either positive or negative along those lines. We say this all the time when we talk. The marketing is an assumption. My thought is that it's probably over the long term around 3%. There's certainly quarters that can be more or less with that. But I would just tell you as we project out as a company and we look for the multiple years, I still call that around a 3% range. With us in particular, I'm happy with where we are. I think there's certainly puts and takes where we're strong in some areas, and we certainly have other places where I think if we can penetrate the right way we can even accelerate. But, just my long-term guess would be around the 3 range. I couldn't tell you what I thought it was for first or second quarter so far this year.
Keith Pfeil: Steve, just one comment I would add to Dan is one of the things that we've historically looked at Globus is the introduction of new products to offset price. I think with the first two quarters you've seen us come to market with five new products in Q1 and another four this quarter. That strategy of bringing new product to market is hitting, and that's something that will help us offset prices. We see it now or in the future.
Steve Lichtman: Got it. And then thanks, guys. And then just one to follow up on R&D expense. You took that down for the year. It came in lower in the quarter. Any change in philosophy there, or are you sort of resetting projects as you integrate? Can you talk a little bit about how you're viewing investment in R&D overall now?
Keith Pfeil: So the team is still focused on bringing new products to market. That has and will remain the same moving forward. Really, as I look at this, it's really more cost control around third-party spending, consulting spending, and things like that. As you know, Globus would like to do a lot of things in-house. That strategy is moving forward, and it's really a testament to the teams coming together, Dan commented about improved internal development process. You're seeing some of that coming in numbers.
Daniel Scavilla: And, Steve, I would also just elaborate. We have not reduced or changed any in-process projects. We remain committed to putting them through.
Steve Lichtman: Got it. Thanks, guys.
Operator: Thank you. One moment for our next question. We have a question from David Saxon of Needham & Company. Your line is now open.
David Saxon: Great. Good afternoon, Dan and Keith. Thanks for taking my questions and congrats on the quarter. Maybe I'll start with guidance, both revenue and earnings. So you beat by about $14 million, $15 million. You raised the bottom by $10 million, top by $5 million. So I guess anything you're seeing in the market that is giving you pause for not raising by the full beat? And then kind of similar question on earnings. It looks like R&D maybe goes down, tax might come up. Does tax just more than offset all that, and that's why we're not seeing the full beat come through?
Daniel Scavilla: So great question. As we think about top line, I think it goes back to what we talked about the last couple of quarters. Every quarter we get more and more confident. We did the raise this quarter. We know we're still not through a full 12 months. We remain appropriately conservative, but we gain more and more confidence every day in the business. As I think about the bottom line, I think that the team has executed pretty well the first half of the year. I did call out last quarter that there was a six and one-timer related to depreciation that we don't expect to repeat. It was a non-cash add back. But as I looked to the second half, all signs pointed to the business operating as we had intended. We're again remaining appropriately conservative because we want to get through another quarter to see how things turn out. But all signs point to this business, operating well according to what we had expected.
David Saxon: Okay. Super helpful. Maybe a quick follow-up on that. So do you view 12 months as kind of the milestone after which we might kind of have a "all clear moment"? And then my follow-up is just on the sales dissynergy assumption. Is that still 150 or how's that tracking this year? Thanks so much.
Daniel Scavilla: So I would say that, as each quarter passes we feel more and more confident. You have to remember what we've done. We went very fast since this deal was announced. We brought maximum disruption to the sales force and really to the interoperability, bringing the systems together, coming forward with new ways for them to go forward to sell cross-selling. There's a lot of disruption. So as we think about that first year, we want to make sure that we go fast but still maintain conservatism. The team has really come together. We've worked through issues and as we sit today, I feel more confident today than I did the previous quarter, but I'm still understanding I'm still within 12 months. As it relates to the dissynergy, the $150 million, again, as each quarter passes we feel more and more confident. In some of my earlier prepared remarks, I talked about having consecutive growth in the musculoskeletal portion of the business as well as consecutive growth in the U.S. portion of the business. Those comments should help to indicate that we're getting more and more confident as we look ahead.
Keith Pfeil: Yes, and what I would build up to is certainly we're looking to reach steady state by the end of the year. So I would tell you that it's more of a 12 to 18 month type of approach for us to get where we want to be. But keep in mind, too, this is even though we're in a strong spot right now, this is a point where we lean forward and push harder, not step back. We've got a lot of heavy lifting to do. We're mindful of that. We want to be appropriately conservative. We want to make sure we drive this well beyond where it needs to be to get this done right.
David Saxon: Great. Thanks so much, and congrats, again.
Keith Pfeil: Thank you.
Operator: Thank you. Our next question comes from the line of Matthew O'Brien, Piper Sandler. Your line is now open.
Matthew O'Brien: Afternoon. Thanks for taking that question. Dan, I know you said you didn't want to talk about next year too much here and I understand that. I just -- as I look at the street where we're all modeling things for next year, it's about $180 million absolute increase. If you go back and look at GMED stand-alone and NUVA stand-alone, each of you would do something like 80 and then 60. So that's about $140 million absolute improvement. So as I think about that $140 versus the $180 that the street's modeling, there's a delta there. At the same time, you're still trying to integrate these teams, and you're cutting some spending, et cetera. So maybe back to Steve's question in a long-winded way, the market's growing three. Can you double that next year or is that how we should think about the combined entity for the next several years is doubling or even a little bit more the overall market rate?
Daniel Scavilla: Yes, and I appreciate, Matt thanks. So a couple things. We are going to strive to be a high single, low double-digit grower even through this merger approach. It is honestly too early for me to comment on where we'll be next year. Like I said, we've got a lot in front of us for now. We are going to have the analyst day and a longer look, so I think we can have a deeper conversation later in the year. So regardless of where consensus or the market is versus where we are, let's go have those conversations and see where we adjust that. But for right now, don't want to go deeper into next year with everything that's in front of us for the second half of this year.
Matthew O'Brien: Got it. And then the follow-up is just on the reimbursement side. It looks like there is a pretty meaningful inpatient cut to single-level cases in the final rule. So I'm just curious how that could impact your business and then how you're positioned for that on the ASC side, because I know that's been a bigger push recently. Thanks so much.
Daniel Scavilla: Yes, I would tell you right now, we're not modeling or coming off track with anything we see related to the reimbursement that's occurred. I don't think we're going to signal that that's an issue. I don't think you've heard that literally from anyone else who's announced so far through the year or through the quarter -- excuse me, with that. And I would say with an ASC strategy, again, we like others have things that are in process and constantly developing and evolving and we'll take a look at that. If this becomes a significant ASC approach, we'll react accordingly. But I'll be honest with you, with the bag we have and the opportunity we have throughout ASCs, I feel really confident regardless of where this can go that we're poised to do it and do it better than anybody else.
Matthew O'Brien: Got it. Thank you.
Operator: Thank you. Our next question comes from the line of Jason Wittes of ROTH. Your line is now open.
Jason Wittes: Hi. Thanks for taking the questions. First off, in terms of synergies and cross-selling opportunities, have they evolved this quarter or are we still waiting to see those on a meaningful level? And how do you see it progressing for the rest of the year?
Daniel Scavilla: Jason, it's Dan. So let's start with that is we do see cross-selling continue. To be honest, the more you do it with the teams, it gets a little bit blurred, so I don't have a precise number to put out for you with that type of thing. But we know the training's occurring. We see the teams sharing and cross-selling. We still have a decent amount of products to come in from our suppliers that can further help us with that. But what I think is it's occurring, it's getting incrementally better each quarter. And I think as the products arrive and we deploy them out to our teams, we'll see some lifts with that. I think it was easy up front to model what it is, but as you execute and blend, it gets tougher, a little bit blurrier to see. That's why I don't throw out a number. But I'm happy with it. I do see it as a potential. And back to kind of Matt's question that was there before, I see that as one of the best ways to have a growth driver that goes above market as we really execute.
Keith Pfeil: And just to add on to some of Dan's comments, I would expect the ability to cross-sell to improve as time passes, because you have to remember some of the -- earlier comments where Dan and I talked about investments, we've driven investments in new sets. Some of the legacy and invasive products had a longer lead time because many of those products came from third-party vendors. As those products start to come in, that will drive greater ability for both legacy teams to cross-sell because there will be more product on hand.
Jason Wittes: But it sounds like from your commentary that this, it sounds like the second half of this year is when we start seeing that, given what's going with supply. Am I hearing that correctly?
Daniel Scavilla: No, it's occurring today. It's occurring at an incremental pace each time we do this. It's getting better. And we have on order, honestly, a large amount of sets to further enhance that going forward. But what I'm telling you is we're blending the teams. It's really tough to look at a NuVasive versus a Globus at this point because they are teams and they act as one. So we're going to fuel them out. And what I think is we'll just see a natural lift in our sales based on these teams applying this, whether it be cross-selling or penetrating existing customers.
Jason Wittes: Got it. Thanks. Maybe, just a quick follow-up to a previous question. You were asked about dissynergy. And I think if I heard correctly, 150 to 200 was kind of the number you put out at the beginning. And it sounds to me like really until we're past, I think you said, 12 to 18 months, you're not willing to revisit that number. Am I thinking about that correctly as well? Is that kind of the way you're thinking about looking at your numbers and what the outlook might be and what the dissynergy may eventually come to be?
Daniel Scavilla: I think so. It's certainly 12 months and I would say 18 months up to the limit, right. So we have activities that are occurring. And I just think that by that 18-month period, we'll know for certain where we are. There's still a lot of things in play. Not worried about anything, but just saying as we continue to work through, I'm not in a position now to speak with confidence and say this is where it will finally be. I think we want to get another quarter or two under our belts to call that.
Jason Wittes: That's very fair. And thank you very much. I'll jump back in queue. Thank you.
Operator: Thank you. Our next question comes from the line of Matthew Blackman of Stifel. Your line is now open.
Matthew Blackman: Good afternoon, everybody. Can you hear me, okay?
Daniel Scavilla: Yes.
Matthew Blackman: Okay, great. Maybe, if I could start. Dan, just a clarification. I think you mentioned needing a couple of approvals for NuVasive hardware on the robot. Could you just remind us those two products you talked about and the timing? And then I've got a follow-up, a couple of follow-ups to that.
Daniel Scavilla: Yes, no problem. What I was saying in my script was we will put NuVasive products on there. For example, we want a modulus to be the two obvious, a pedicle screw and an inner body type of thing. And when we get that software and the things done, which we're in the process of doing, we should open up a larger customer base. So if we've got surgeons who are using those and are waiting to use those, once it's in our software and with our instrumentation, we would expect to see that lift and, therefore, more sales occurring with NuVasive-based surgeons.
Matthew Blackman: Okay, understood. And just on that point, I think you had already started engaging some of these accounts in the first quarter, maybe even started quoting some of them. Were there any placements or sales this quarter, just out of curiosity? And then I do have one follow-up.
Daniel Scavilla: There was one sale that we closed thus far related to a legacy NuVa account. As I think about the quoting volume and, really, the pipeline, there's strong interest on both sides. And to me, the amount of quotes we're putting out continues to increase.
Matthew Blackman: Okay. That's great. My final question, I swear, this is a little bit off the reservation, but I think maybe one of the underappreciated pieces of the portfolio that we're all going to probably see more and more about, is the power tool launches. I'm just hoping maybe you could frame that opportunity for us and how you're thinking about that contributing into all the other sort of growth vectors you have over the next several years? Thanks.
Daniel Scavilla: Yes, will do, and thanks. It is one of the things I've said before that I'm most excited about this year. We have a great, as you know, cadence right now with product launches, but that in particular we consider to be transformational. The fact that you can go out with that bone removal without soft tissue damage allows the surgeon, to move freely where they want, to not be restricted by artificial boundaries, or other type things that can hinder what they want to do. And so, not only does it create that freedom and put more into the hands of the surgeon, I think that it can also make it safer by not having to dual tears, or other type of items that can occur. So I think that that in itself as we scale up, and there's really a lot of hot interest for it in the field, will continue for the years to come, and it will be one of the main growth drivers that we have.
Matthew Blackman: Thanks so much.
Operator: Thank you. Our next question comes from the line of Ryan Zimmerman of BTIG. Your line is now open.
Ryan Zimmerman: Hi, thanks for taking our questions, guys. I want to ask, you know, a lifetime ago, Dan, you talked about robotics and the ability for pull-through. And this was, back in I think even 2018, 2017, when Excelsius was just launching. And at the time we thought about, one incremental case per week, and we kind of built an assumption around the incremental volumes that Globus would get from robotic adoption. Fast forward today, and you've added a lot more to Excelsius. And so, I'm wondering if you can kind of just, opine a little bit on, that pull-through impact, kind of what you're seeing in the field today versus maybe when robotics was more in its infancy, and whether our assumption of, one incremental case as a result, is maybe stale at this point?
Daniel Scavilla: Thanks, Ryan. So what I think is this. When you place a robot, we see and we continue to see a lift in the implant pull-through, whether that be more procedures or more usage, or several surgeons interested in doing that. That's kind of what we started with assumptions, and that remains today. And there can be a whole range depending on where you are and what they're doing. But, I would say if you want to pick even a 20% lift for a period of time that occurs, possibly even more of pull-through as it's new. Now, obviously, that neutralizes over time. It's not going to create each account that way. But the good news is the robotic market in total is still in its infancy and very underpenetrated in total. And so, there's still a lot of that growth that can occur throughout, and I think that's really where it is. So the assumptions, whether it be one case or not, I don't know because it depends on how many cases they're using. But if you pick something where you'd say conservatively 15% to 25% of pull-through in that first year. And then remaining per robot, that's what I think you can model in and see as we go forward and what we've experienced since launch.
Ryan Zimmerman: Very helpful. Maybe turning to Keith, at some point you're starting to generate some really nice free cash flow. Again, before the merger you generated a lot of cash flow. What are you going to do with the cash, Keith? And how should we think about your capital allocation, especially as we're kind of lapping this merger now?
Keith Pfeil: That's a great question. So I think about capital allocation, number one, Globus is going to maintain strong balance sheets, part of our cultural culture and will remain. Capital allocation is going to be focused on internal development from an R&D perspective, machinery and equipment. We've talked a lot about, driving additional insourcing in the near term here. As I think about longer term, I would absolutely think that we're going to continue to look at M&A opportunities within our core of musculoskeletal. I don't see us venturing outside of musculoskeletal, but as we move the business forward after we've digested this merger, I would expect us to become active again on the M&A front.
Ryan Zimmerman: Thank you.
Keith Pfeil: Thank you.
Operator: Thank you. Our next question comes from the line of Richard Newitter of Truist. Your line is now open.
Ravi Mishra: Hi, good evening. This is Ravi Mishra for Rich. I wanted to ask about Excelsius and the kind of TKA program. You're talking a little bit about rep hiring. If you could get a little bit of clarity around that, what kind of approach are you going from a channel perspective, direct reps versus capital reps, and what kind of, ASC versus inpatient, outpatient, how are you thinking about that opportunity ahead of you?
Daniel Scavilla: Thanks, Ravi. So the answer is kind of all of the above. Very similar to what we have done with spine, what we've done with trauma. We intend to have our own standalone sales force. We certainly want it to be direct. It doesn't mean there's not an exception somewhere therein. But, we build it in concentric circles. We're not going to go out and say, let's go hire 400 reps and see what happens. We're going to take it as we always do in a de-risk approach, grow into it, move on type approach. The answer to where the focus is all of the above. We're going to go to where the customers are, and where the procedures occur in order to be meaningful. And so, it's not one in particular, but rather how you approach all of them that way. And the thought will be certainly a handful of capital reps in addition to folks who are working with the knees, just to help facilitate it through. But nowhere near the size of what I think we need for spine right now. And I think the real thing is, too, we're not going to detract the focus of our spine capital folks, given the opportunity that's ahead of us. This is going to be something that we do in addition. But if you know us, we know that we control our costs, we control our investment. You're not going to see a degradation of our numbers as we move forward into growth.
Ravi Mishra: Great. And then maybe, you mentioned this aspiration to get back to low double-digit, high single-digit growth. How does Excelsius factor into that? Is that kind of incremental to that high single-digit that consensus has next year? If you could just help think about that layering? Thanks.
Daniel Scavilla: No, it's going to be all the above type things, right? So anything you do with enabling tech is going to be to facilitate implant pull-through. And so as I speak about those ranges, it's as one company, and it's utilizing everything to get there.
Operator: All right. Thank you. [Operator Instructions] Our next question comes from the line of Craig Bijou of BofA. Your line is now open.
Craig Bijou: Good afternoon, guys. Thanks for taking the questions. I wanted to start on the enabling tech side. And the comments you guys made on the acceleration of the rental program and revenue was up 6% but you guys had a lot of unit placements - record robot unit placements. So I guess specifically, what's driving the acceleration of the rental program? Is it across the enabling tech, so 3D as well and even the knee robot? And then, what's the potential that it becomes a headwind because you are recognizing revenue over a longer time period versus the capital sale?
Keith Pfeil: Yes. Thanks, Craig. So, a couple things. I would tell you that it's just more customer preference for the rental side. It's something we've always offered, but it seems to be taking on a little bit more right now. It doesn't mean that we're announcing that we've become a rental company. It's just going to be we'll sell where we can, we rent where we can. There's obviously leases out there as well. I'm not overly concerned about that blend suddenly taking us off revenue targets. I think if anything, I look at it like an annuity. Several of them, if not all of them, are pretty short-term anyway. And one of the thoughts would be that they lead into a sale. And so, I would tell you we're going to stay the course. If customers want to rent these, see if they convert into sales, great. But at the end of the day, I don't think it's anything that you'd see a slowdown, or anything like that. I think what you had for this quarter is unique. First off, you had a strong comp last year. We had really good stuff that you're going against, which might have slowed it down to that 6%. But the unit placement, again, is probably more of a rev-rec thing, which I just think we had a lift in this for the rentals. And we'll take that all day long, because we've played for the long-term. And so, if that's what we do for a couple of quarters and move on to other things, so be it.
Craig Bijou: Got it. That's helpful. And maybe combining that question with one of the earlier questions on the ASC or surgeries moving to the ASC. How do you guys think, or what are you willing to disclose about targeting ASCs with your enabling tech and you're driving business that way?
Keith Pfeil: I think it depends on the ASC and what they need, right. We want to sell the appropriate things in that will facilitate them treating customers the best way. And so, we have already been there, and there are cases where they need a robot, there are cases where they need just hand navigation through the hub. I think we're really positioned to do that the best way that they want. One thing I do want to put out is we're active with ASCs, so I want to make sure we don't have the impression that it's something we're looking into. We are active there already. And it really, again, just depends on what those surgeons want and what's best for their customers given their size - and what their throughput is.
Craig Bijou: Great. Thanks, guys. Thank you. Our next question comes from the line of Matt Taylor of Jefferies. Your line is now open.
Young Li: All right. Great. Thanks so much. This is Young Li on for Matt. Can you provide us with some more color on the trauma business? It seems to be doing well and contributing to U.S. growth. Maybe if you can talk a little bit more about the drivers of that and the sustainability of that?
Keith Pfeil: Sure, Young Li. It's one of those long-term plans we've talked about since launching it in that it's going to be continuous and incremental growth similar to spine. So you're penetrating that market. You're going to be contributing that way. So one of the factors of that growth is simply that we're penetrating the market as we add and make headway. The reason we're penetrating the market and creating headway is we've been decent at launching products, especially in the past year. And through the rest of this year, further allowing you to open up more areas to compete. And so, you've got that rep hiring, market penetration, product launches. One of the biggest lifts right away is the NSO now. And that in itself becomes a great product that can really open doors for us and has a big lift. So the combination through the merger with product launches, with market penetration are what's allowing us to gain in the trauma business.
Young Li: Okay. Great. Very helpful. On the Excelsius Prone system, I wanted to hear a little bit about how that stacks up versus the competition, what's differentiated about it, and your thoughts on penetrating to that market?
Daniel Scavilla: Yes, well, not penetrating that market. We created that market for sure through the Invasive team. And that's, again, one of the reasons why we went in and did this merger. We're solid there with that type of approach. This is really enhancements that will further benefit the patient through a solid positioning, allowing you to have a more firmer retractor that's out there. And also create better ergonomics for the surgeon, as they're going in and doing this from the lateral side. I think one of the many benefits to it, too, is marrying this up to work with our enabling technology really creates that holistic package of why we did this. It's marrying enabling technology, expandable cage technology, the incredible new invasive structure of proceduralization altogether. I think that's really where we come out strong, and I think, if anything, we'll stay strong in this area. And, of course, you've heard me dabble in on the neuromonitoring and how we're going out to expand that further and even enhance that capability. So all of the above, I think, will add into a very strong position in that procedure.
Operator: All right. Thank you. Our next question comes from the line of Ravi Mishra of Truist. Your line is now open.
Ravi Mishra: Hi. Thanks for the follow-up. Just two housekeeping questions. On the selling days, how do we think about that in the back half of the year? And, second, on the convert in March, should we kind of think about that as paying that down or rolling it forward? Thanks. Appreciate the follow-up.
Keith Pfeil: In the back half of the year, there's one more day in Q3, one more day in Q4. As it relates to the convert, you are correct. We will look to settle those notes when they are due in cash. That's the current intent. If anything changes, we will report out on our next earnings call. But I don't see anything changing there.
Ravi Mishra: Thanks a lot.
Operator: All right. With no further questions, this concludes the Globus Medical Earnings Call. Thank you for participating. You may now disconnect.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.